Johnson & Johnson acquires Halda Therapeutics for $3 billion to strengthen its oncology portfolio, focusing on prostate cancer therapies. The acquisition includes HLD-0915, a clinical-stage therapy ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics announced today new data from a Phase 1/2 study evaluating HLD-0915, a first-in-class, oral RIPTAC™ therapeutic, in patients with ...

This content is provided by an external author without editing by Finextra. It expresses the views and opinions of the author. Today, Mastercard is introducing two new innovations – Commercial Connect ...

New York-based Looking Glass Factory (LGF) has been narrowly focused on making glasses-free holograms a thing with its innovative displays. For its latest trick, it's devised a screen that can present ...

In preclinical prostate cancer models, HLD-0915 treatment resulted in tumor shrinkage and declines in prostate-specific antigen. The Food and Drug Administration (FDA) has granted Fast Track ...

HLD-0915 has received FDA fast track designation for mCRPC, expediting its development and review process to address unmet medical needs. Halda Therapeutics is conducting a phase 1/2 clinical trial to ...

NEW HAVEN, Conn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of therapies called RIPTAC™ Therapeutics, today announced that ...

It’s widely recognized that the crises of loneliness, disconnection, and social fragmentation are touching nearly every aspect of our lives, from personal well-being to public health to democracy ...